27th July, 2016

The Dy. General Manager (Listing Dept.)
BSE Limited
Corporate Relationship Dept.,
1st Floor, New Trading Ring,
P. J. Towers, Dalal Street, Fort,
Mumbai - 400 001
(BSE Scrip Code: 500420)

The Manager – Listing Dept.,
National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G. Block,
Bandra - Kurla Complex, Bandra (E),
Mumbai – 400 051
(NSE Scrip Code: TORNTPHARM)

Dear Sir,

Re: Proceedings of 43rd Annual General Meeting of the Company held on 27th July, 2016

In terms of Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), we hereby inform you that the following businesses were transacted at the 43rd Annual General Meeting (AGM) of the Company held on 27th July, 2016:

1. Approval and adoption of Standalone and Consolidated Financial Statement as at 31st March, 2016, including the Audited Balance Sheet as at 31st March, 2016, the Statement of Profit and Loss for the year ended on that date and reports of the Board of Directors' and Auditors' thereon.

2. Confirmation of payment of normal annual dividend of ₹ 20/- as an interim dividend and a special dividend of ₹ 15/- as second interim dividend on each fully paid up equity shares of face value of ₹ 5.00 declared and distributed by the Board of Directors for the financial year ended on 31st March, 2016.

3. Re-appointment of Shri Samir Mehta (holding DIN 00061903) at the aforesaid AGM who retired by rotation and was eligible for re-appointment.

4. Appointment of Deloitte Haskins & Sells, Chartered Accountants, Ahmedabad (Firm Registration No. 117365W) as Statutory Auditors of the Company to hold office from the conclusion of this AGM until the conclusion of the next AGM and to authorize Board to fix their remuneration.

5. Ratification of remuneration of cost auditors of the company for the year 2016-17.

The above businesses were transacted by Poll at the meeting as required under Companies Act, 2013 and Listing Regulations. Results of the passing of above resolutions as required under Regulation 44(3) of Listing Regulations will be disclosed to the Stock Exchange separately.

Kindly take note of the above.

Yours Sincerely,

For TORRENT PHARMACEUTICALS LIMITED

MAHESH AGRAWAL
VP (LEGAL) & COMPANY SECRETARY